The French Competition Authority announced its approval for a pending merger between pharmaceutical giants Actavis and Warner Chilcott, say reports. Actavis’s buyout of Warner Chilcott remains pending. The German Federal Cartel Office has similarly cleared the deal and, according to a press release, the parties have now obtained permission from all ex-US antitrust regulators. Financial details of the deal were not made public. Actavis, based in the US, recently went head-to-head with the US Federal Trade Commission in the Supreme Court; the Court found that so-called pay-for-delay deals, which delay cheaper, generic forms of pharmaceuticals from being sold, can be subject to antitrust lawsuits.
Featured News
Sources Report Glimmers of Progress in Talks to Resolve Conflicts Over Crypto Market Structure Bill
Jan 9, 2026 by
CPI
CFTC Certifies First Crypto-Native Exchange as a Designated Contract Market
Jan 9, 2026 by
CPI
Glencore and Rio Tinto in Talks Over Deal That Could Create $260 Billion Mining Giant
Jan 8, 2026 by
CPI
Google, Meta, Amazon, Microsoft, Netflix Set to Avoid Tough EU Curbs: Report
Jan 8, 2026 by
CPI
EU Antitrust Review of Google-Wiz Deal Draws Intense Scrutiny Ahead of 2026 Deadline
Jan 8, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi